We are proud to collaborate with the Angelman Syndrome Foundation, the Dup15q Alliance in Linking Angelman and Dup15q Data for Expanded Research (LADDER).
Investigating the occurrence of food sensitivity and the relationship with gut microbiome in Angelman syndrome could lead to dietary intervention to help to reduce or alleviate symptoms
Two press releases were issued recently with one announcing an Exclusive Option Agreement between GeneTx Biotherapeutics, LLC (“GeneTx”) and Ultragenyx Pharmaceutical, Inc. (“Ultragenyx”), and the other announcing GeneTx’s lead candidate receiving Orphan Drug Designation (ODD) and Rare Pediatric Drug Designation (RPD). GeneTx would like to take this opportunity to provide additional information to our community about this very exciting news.
Felicity Williams joins the FAST board. Felicity’s combination of medical knowledge and position as a parent will be a asset to our team.
FAST Australia announces a new two-year Angelman syndrome research fellowship for Dr Emma Baker at the Murdoch Children’s Research Institute.